Clinical Evaluation of CEA , CA125, CA19-9 and CA72-4 in Gastric Cancer Patients with Adjuvant Chemotherapy

M. Abbas,S. Fransis,M. Naveed,I. S. Mohammad,C. Tengli,A. Nepal,D. T. Thao,S. Meiqi,C. Dingding
DOI: https://doi.org/10.1016/j.jval.2017.08.1996
IF: 5.156
2017-01-01
Value in Health
Abstract:In the clinical practice, We aimed to investigate whether tumor markers CEA , CA125, CA19-9 and CA72-4 can be used to evaluate the response to adjuvant chemotherapy, and to evaluate the diagnosis and prognosis value of 4 tumor markers in the patients of gastric cancer. A retrospective study was performed of 216 gastric cancer patients who underwent a first line cisplatin chemotherapy and anti-angiogenic agents regimen. Statistical analysis was performed to identify the clinical value of these tumor markers in predicting the progression free survival and the response to adjuvant chemotherapy. Progression occurred in 78 of 216 patients and overall median progression free survival was 5-Months. For serum CEA, the median PFS was 4 versus 7 Months for elevated and normal groups (P = 0.01). The median PFS for normal and elevated CA199 and CA72-4 was 6 versus 4 months (P = 0.001). In the multivariate Cox regression model elevated pre-treatment level of CEA, CA199 and distant metastases were independent factors associated with increased risk of progression (p = 0.021, p = 0.000, p = 0.006). Furthermore, patients presented with combined three or four elevated tumor markers showed worse prognosis and shorter PFS (p = 0.001). The decrease of tumor markers CEA, CA199 and CA72-4 was significant after adjuvant chemotherapy (p = 0.006, p= 0.001, p =0.002) especially in the disease control group (CR+ PR+ SD) (p = 0.03, p = 0.001, p = 0.002) and in patients using anti-angiogenic agents with first-line platinum-based chemotherapy (3-drugs therapy) (CEA, CA199 and CA72-4; p = 0.005, p =0.0006, p = 0.001). Our result suggests that elevated pre-treatment level of CEA and CA199 are correlated with high risk of progression and worse prognosis, while the use of anti-angiogenic agents with first-line platinum-based chemotherapy more effective in decreasing tumor markers level after adjuvant chemotherapy.
What problem does this paper attempt to address?